Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Allografting

Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma

Bone Marrow Transplantation volume 27, pages 801–807 (2001)Cite this article

Abstract

This study compares the probability of disease progression, progression-free survival, and overall survival between patients undergoing an allogeneic or autologous transplant for multiple myeloma using an identical preparative regimen. Patients received a preparative regimen of TBI, busulfan, and cyclophosphamide followed by an allogeneic or autologous transplant. In the allogeneic group (n = 21), six patients received bone marrow and 15 received G-CSF mobilized PBSC; all autologous patients (n = 35) received PBSC mobilized with cyclophosphamide and G-CSF. Allogeneic donors were HLA-identical (n = 20) or one-antigen mismatched (n = 1) siblings. Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus (n = 10), tacrolimus/methotrexate (n = 6), cyclosporine/methotrexate (n = 4), or cyclosporine (n = 1). The groups were evenly matched for gender, pretransplant therapy, disease status at time of transplant, myeloma subtype, and time from diagnosis to transplant. The median age was significantly lower in the allogeneic group (48 vs 55 years, P < 0.01). In the allogeneic group the probabilities of developing acute GVHD grade II-IV and chronic GVHD were 55% and 82%, respectively. The Kaplan–Meier probability of disease progression was significantly lower in the allogeneic group (11% vs 64%, P < 0.001) compared to the autologous group. Although progression-free (60% vs 30%, P = 0.19) and overall survival at 2 years (60% vs 42%, P = 0.39) favored the allogeneic group, this did not reach statistical significance. Within the allogeneic transplant group, patients age 50 years or under had a 3-year overall survival significantly higher when compared to older patients (79% vs 29%, P = 0.03). Using identical preparative regimens, allogeneic transplantation reduced disease progression compared to autologous transplantation for myeloma. This suggests that allogeneic transplantation induces a graft-versus-myeloma (GVM) effect. Bone Marrow Transplantation (2001) 27, 801–807.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Cunningham D, Paz-Ares L, Gore ME et al. High-dose melphalan for multiple myeloma: long-term follow-up data J Clin Oncol 1994 12: 764–768

    Article  CAS  PubMed  Google Scholar 

  2. Barlogie B, Hall R, Zander A et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma Blood 1986 67: 1298–1301

    CAS  PubMed  Google Scholar 

  3. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome New Engl J Med 1996 335: 91–97

    Article  CAS  PubMed  Google Scholar 

  4. Gahrton G . Treatment of multiple myeloma Lancet 1999 353: 85–86

    Article  CAS  PubMed  Google Scholar 

  5. Mehta J, Singhal S . Graft-versus-myeloma Bone Marrow Transplant 1998 22: 835–843

    Article  CAS  PubMed  Google Scholar 

  6. Bjorkstrand BB, Ljungman P, Svensson H et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation Blood 1996 88: 4711–4718

    CAS  PubMed  Google Scholar 

  7. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases Blood 1998 91: 756–763

    CAS  PubMed  Google Scholar 

  8. Bacigalupo A . Hematopoietic stem cell transplants after reduced intensity conditioning regimen (RI-HSCT): report of a workshop of the European Group for Blood and Marrow Transplantation (EBMT) Bone Marrow Transplant 2000 25: 803–805

    Article  CAS  PubMed  Google Scholar 

  9. Lokhorst HM, Sonneveld P, Cornelissen JJ et al. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma Bone Marrow Transplant 1999 23: 317–322

    Article  CAS  PubMed  Google Scholar 

  10. Varterasian M, Janakiraman N, Karanes C et al. Transplantation in patients with multiple myeloma: a multicenter comparative analysis of peripheral blood stem cell and allogeneic transplant Am J Clin Oncol 1997 20: 462–466

    Article  CAS  PubMed  Google Scholar 

  11. Bensinger WI, Rowley SD, Demirer T et al. High-dose therapy followed by autologous hematopoietic stem-cell infusion for patients with multiple myeloma J Clin Oncol 1996 14: 1447–1456

    Article  CAS  PubMed  Google Scholar 

  12. Bensinger WI, Buckner CD, Anasetti C et al. Allogeneic marrow transplantation for multiple myeloma: an analysis of risk factors on outcome Blood 1996 88: 2787–2793

    CAS  PubMed  Google Scholar 

  13. Durie BG, Salmon SE . A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival Cancer 1975 36: 842–854

    Article  CAS  PubMed  Google Scholar 

  14. Uberti JP, Silver SM, Adams PT et al. Tacrolimus and methotrexate for the prophylaxis of acute graft-versus-host disease in allogeneic bone marrow transplantation in patients with hematologic malignancies Bone Marrow Transplant 1997 19: 1233–1238

    Article  CAS  PubMed  Google Scholar 

  15. Cox DR . Regression models and life-tables J Stat Soc 1972 34: 187–220

    Google Scholar 

  16. Kaplan EL, Meier P . Nonparametric estimation from incomplete observations J Am Stat Assoc 1958 53: 457–481

    Article  Google Scholar 

  17. Kulkarni S, Powles RL, Treleaven JG et al. Impact of previous high-dose therapy on outcome after allografting for multiple myeloma Bone Marrow Transplant 1999 23: 675–680

    Article  CAS  PubMed  Google Scholar 

  18. Desikan KR, Tricot G, Dhodapkar M et al. Melphalan plus total body irradiation (MEL-TBI) or cyclophosphamide (MEL-CY) as a conditioning regimen with second autotransplant in responding patients with myeloma is inferior compared to historical controls receiving tandem transplants with melphalan alone Bone Marrow Transplant 2000 25: 483–487

    Article  CAS  PubMed  Google Scholar 

  19. Barlogie B, Jagannath S, Naucke S et al. Long-term follow-up after high-dose therapy for high-risk multiple myeloma Bone Marrow Transplant 1998 21: 1101–1107

    Article  CAS  PubMed  Google Scholar 

  20. Gahrton G, Svensson H, Apperly J et al. Progress in allogeneic hematopoietic stem-cell transplantation for multiple myeloma Bone Marrow Transplant 2000 25: (Suppl. 1) 140a

    Google Scholar 

  21. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers New Engl J Med 2001 344: 175–181

    Article  CAS  PubMed  Google Scholar 

  22. Powles R, Mehta J, Kulkarni S et al. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: a randomised trial Lancet 2000 355: 1231–1237

    Article  CAS  PubMed  Google Scholar 

  23. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor lymphocyte infusions for relapsed multiple myeloma after allogeneic stem-cell transplantation: predictive factors for response and long-term outcome J Clin Oncol 2000 18: 3031–3037

    Article  CAS  PubMed  Google Scholar 

  24. Lokhorst HM, Schattenberg A, Cornelissen JJ et al. Donor leukocyte infusions are effective in relapsed multiple myeloma after allogeneic bone marrow transplantation Blood 1997 90: 4206–4211

    CAS  PubMed  Google Scholar 

  25. Tricot G, Vesole DH, Jagannath S et al. Graft-versus-myeloma effect: proof of principle Blood 1996 87: 1196–1198

    CAS  PubMed  Google Scholar 

  26. van der Griend R, Verdonck LF, Petersen EJ et al. Donor leukocyte infusions inducing remissions repeatedly in a patient with recurrent multiple myeloma after allogeneic bone marrow transplantation Bone Marrow Transplant 1999 23: 195–197

    Article  CAS  PubMed  Google Scholar 

  27. Martinelli G, Terragna C, Zamagni E et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma J Clin Oncol 2000 18: 2273–81

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported in part by the General Clinical Research Center of the University of Michigan (M01-RR00042).

Author information

Authors and Affiliations

  1. Departments of Internal Medicine, Radiation-Oncology, and Biostatistics, University of Michigan Blood and Marrow Transplantation Program, Ann Arbor, MI, USA

    C Reynolds, V Ratanatharathorn, P Adams, T Braun, S Silver, L Ayash, E Carson, A Eisbruch, LA Dawson, K McDonagh, J Ferrara & J Uberti

Authors
  1. C Reynolds
    View author publications

    Search author on:PubMed Google Scholar

  2. V Ratanatharathorn
    View author publications

    Search author on:PubMed Google Scholar

  3. P Adams
    View author publications

    Search author on:PubMed Google Scholar

  4. T Braun
    View author publications

    Search author on:PubMed Google Scholar

  5. S Silver
    View author publications

    Search author on:PubMed Google Scholar

  6. L Ayash
    View author publications

    Search author on:PubMed Google Scholar

  7. E Carson
    View author publications

    Search author on:PubMed Google Scholar

  8. A Eisbruch
    View author publications

    Search author on:PubMed Google Scholar

  9. LA Dawson
    View author publications

    Search author on:PubMed Google Scholar

  10. K McDonagh
    View author publications

    Search author on:PubMed Google Scholar

  11. J Ferrara
    View author publications

    Search author on:PubMed Google Scholar

  12. J Uberti
    View author publications

    Search author on:PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Reynolds, C., Ratanatharathorn, V., Adams, P. et al. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant 27, 801–807 (2001). https://doi.org/10.1038/sj.bmt.1703006

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703006

Keywords

This article is cited by

Search

Advanced search

Quick links